Brent Barre is a research associate with Lovelace Biomedical Research Institute where he currently works with multiple SARS-CoV2 virus studies, in addition to other infectious diseases as well as chemical agents.
We are pleased to share an interview with Brent, who kindly gave us some of his valuable time to share his thoughts about his current research.
I work with different pathogens (viral pathogen (COVID, Flu), bacterial pathogens (anthrax, tularemia), biological pathogen (ricin)) that require testing in a BSL3 facility. Most of these are classified as infectious diseases.
I have been in CMO/CROs for more than 17 years.
Lovelace has been working with infectious disease models over 70 years.
I currently work on multiple active SARS-CoV2 (COVID-19) studies on-going in our BSL3 facilities.
Given the current global concern of SARS-CoV2 (COVID-19), it fosters a more collaborative research environment as we are all working toward helping our own communities to find treatment and vaccine options for patients.
We are looking at respiratory outcomes such as respiratory rate (RR), tidal volume (TV), minute volume (MV), and accumulated volume (AV) as well as temperature for onset of fever which are currently used in the clinics to diagnose COVID-19 patients and determine disease severity.
To begin our SARS-CoV2 (COVID-19) studies we began looking at models that showed promise in previous SARS-CoV and influenza studies. Some examples of currently used subjects in the follow, where each have their own pros and cons for the various research goals each institution is working on.
Certain selection criteria are used when looking at any potential subject for inclusion in a research study. In regard to SARS-CoV2 (COVID-19), we are looking at models that show the following:
Both, as both have their own advantages and disadvantages to study the disease in its entirety.
Physiological data such as RR, TV, and MV may be used to calculate pathogen presentation to a subject or used to assess reaction during and/or after a therapy is presented. Accurate baseline measurements are also critical for comparative analysis of individual subjects.
Physiological observations are critical to assess reaction to both pathogens and therapies. For example, TV, MV, and RR data may be collected immediately after a therapy is presented, while subjects are periodically monitored for RR, temperature, activity, etc. over a longer period after treatment.
With some diseases, we will look at additional risk factors. In example, we use genetically modified subjects to better understand and additional risk factors or comorbidities.
The ability to use the same software set-up and many of the hardware components across study designs and subject models, allow for a more cost-effective core facility to investigate infectious diseases and other applications.
THANK YOU, BRENT BARRE, FOR THIS INTERVIEW!
If you have any questions, please contact us!
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.